Starting a JAK Inhibitor for UC or Crohn's: What to Track During the First Three Months

Janus kinase inhibitors, usually shortened to JAK inhibitors, are oral pills used for moderate-to-severe inflammatory bowel disease. Two are approved in the United States for IBD: tofacitinib, sold as Xeljanz, and upadacitinib, sold as Rinvoq. Both work quickly compared with infusions, both carry a boxed warning from the Food and Drug Administration, and both come with a defined schedule of blood tests. The first three months cover induction plus the transition to a maintenance dose, the window where your gastroenterologist decides whether the drug is working and whether it is safe to stay on. A deliberate record during those twelve weeks gives that decision something better than memory to run on.

What starting a JAK inhibitor for ulcerative colitis or Crohn's involves

Tofacitinib is indicated for adults with moderately to severely active ulcerative colitis who have had an inadequate response to or intolerance of one or more tumor necrosis factor blockers. The labeled regimen is 10 mg twice daily for at least 8 weeks, extendable to a maximum of 16 weeks, followed by 5 mg twice daily for maintenance. Upadacitinib carries the same prior-TNF-blocker requirement and is approved for both diseases, with the label specifying induction at 45 mg once daily for 8 weeks in ulcerative colitis and 12 weeks in Crohn's disease, then maintenance at 15 mg once daily, or 30 mg once daily for refractory, severe, or extensive disease.

The two drugs are not interchangeable in guideline terms. The American Gastroenterological Association living guideline for moderate-to-severe ulcerative colitis groups upadacitinib among the higher-efficacy medications and tofacitinib among the intermediate-efficacy medications for patients naive to advanced therapy, while placing both in the higher-efficacy group for patients who have already failed one. The 2025 American College of Gastroenterology guideline lists JAK inhibitors as one of eight advanced therapy classes for moderate-to-severe ulcerative colitis, with endoscopic improvement as the treatment target rather than symptom relief alone.

How long a JAK inhibitor takes to work in IBD

JAK inhibitors act faster than most biologics, so the first few weeks are informative. A post hoc analysis of the phase 3 upadacitinib program found statistically significant improvement in abdominal pain and bowel urgency by week 2 of induction, while meaningful fatigue improvement did not appear until week 8. That split matters when judging progress: urgency and pain are the early signals, and energy lags behind.

The formal endpoints land later. In the three phase 3 upadacitinib trials in ulcerative colitis, clinical remission at week 8 was reached by 26% and 34% of patients on 45 mg compared with 5% and 4% on placebo. In the OCTAVE induction trials of tofacitinib, remission at week 8 was 18.5% versus 8.2% placebo in one trial and 16.6% versus 3.6% in the other. For Crohn's disease, the U-EXCEL and U-EXCEED trials measured clinical remission at week 12, reached by 49.5% and 38.9% of upadacitinib patients versus 29.1% and 21.1% on placebo. Logging stool frequency, rectal bleeding, urgency, and abdominal pain daily from the first dose gives your clinician the same trend line those trials measured.

Labs needed on JAK inhibitors during the first three months

The monitoring schedules differ between the two drugs. For tofacitinib, the label directs clinicians to monitor lymphocyte counts at baseline and every 3 months, neutrophil counts and hemoglobin at baseline and after 4 to 8 weeks and then every 3 months, and to assess lipid parameters approximately 4 to 8 weeks after starting, plus routine liver tests. For upadacitinib, the label calls for neutrophils, lymphocytes, hemoglobin, and liver enzymes at baseline and thereafter according to routine patient management, with lipid parameters assessed approximately 12 weeks after initiation. Both labels also require testing for latent tuberculosis before starting, with treatment of latent infection first.

Inflammatory markers track the disease rather than the drug. AGA guidance uses fecal calprotectin under 150 micrograms per gram together with a normal C-reactive protein to support the absence of active inflammation, and the Crohn's disease guidance applies the same calprotectin threshold with CRP below 5 mg per liter, recommending a strategy that combines biomarkers with symptoms rather than symptoms alone. Record the date and result of every draw, since a lipid or calprotectin value is only interpretable against the one before it.

JAK inhibitor side effects to watch for

Both drugs carry an identical FDA boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. It derives largely from a rheumatoid arthritis safety trial, where malignancies excluding non-melanoma skin cancer occurred more often with tofacitinib than with TNF inhibitors, hazard ratio 1.48, with the highest rates in patients aged 65 and older and in current or former smokers.

Rates in ulcerative colitis populations are lower in absolute terms. Across 9.2 years of tofacitinib exposure in the ulcerative colitis program, incidence per 100 patient-years was 1.80 for serious infections, 3.24 for herpes zoster, 0.27 for major adverse cardiovascular events, 0.18 for pulmonary embolism, and 0.88 for malignancies excluding non-melanoma skin cancer. A separate long-term analysis put herpes zoster incidence at 3.38 per 100 patient-years, with increasing age, lower body weight, and prior TNF inhibitor failure as independent risk factors, and more than 90% of cases non-serious. Shingles is the side effect most likely to appear early, and both labels advise bringing immunizations up to date before starting and avoiding live vaccines during treatment.

Report the same day: a painful rash in a band or cluster, fever or persistent cough, chest pain or shortness of breath, or swelling and pain in one leg.

A three-month tracking checklist

Weeks 0 to 2 establish the baseline: record pre-treatment stool frequency, bleeding, urgency, and pain scores, confirm latent tuberculosis screening and baseline bloodwork were done, note vaccination status, and log the start date and dose. Weeks 2 to 8 track early response and the first safety labs. Watch for the urgency and pain changes the trials detected at week 2, log missed or delayed doses with the reason, and confirm the 4 to 8 week lipid and blood count draw on tofacitinib.

Weeks 8 to 12 cover the induction decision point. Ulcerative colitis patients are assessed for response at week 8, Crohn's patients at week 12, and upadacitinib lipids are checked around week 12. Bring a summarized record: symptom trend, calprotectin and CRP values with dates, side effects with onset dates, adherence gaps, and your questions about dose reduction or continuation.

Whether the answer at week 12 is to step down to a maintenance dose, stay at the higher dose, or switch classes, the decision is stronger when the symptom trend, the lab trail, and the side effect history are written down rather than reconstructed in a short appointment.